Charles River Laboratories has lost 60% of its value due to reduced pharmaceutical R&D spending and the FDA's phase-out of animal testing. The FDA's move to phase out animal testing significantly ...
Charles River Laboratories achieved only 6.5% organic revenue growth in FY23 due to weakness in the broader life science industry. CRL offers a comprehensive range of services to pharmaceutical and ...
Charles River Laboratories International Inc. Annual stock financials by MarketWatch. View the latest CRL financial statements, income statements and financial ratios.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback